What is William Blair’s Estimate for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO) – Equities researchers at William Blair issued their Q1 2025 EPS estimates for shares of Korro Bio in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Minter anticipates that the company will earn ($2.91) per share for the quarter. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.98) EPS, Q3 2025 earnings at ($3.02) EPS, Q4 2025 earnings at ($3.05) EPS, FY2025 earnings at ($11.95) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.14) EPS, Q3 2026 earnings at ($3.17) EPS, Q4 2026 earnings at ($3.20) EPS and FY2026 earnings at ($12.61) EPS.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07. The firm had revenue of $2.27 million for the quarter.

Other equities analysts have also recently issued reports about the stock. Oppenheimer began coverage on shares of Korro Bio in a research note on Friday, January 10th. They set an “outperform” rating and a $155.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Korro Bio in a research note on Thursday. Finally, Royal Bank of Canada lowered their price target on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Korro Bio presently has an average rating of “Buy” and an average price target of $142.57.

Korro Bio Stock Down 7.7 %

NASDAQ:KRRO opened at $21.90 on Friday. Korro Bio has a fifty-two week low of $18.50 and a fifty-two week high of $98.00. The firm’s fifty day simple moving average is $30.11 and its 200-day simple moving average is $41.56.

Institutional Investors Weigh In On Korro Bio

Large investors have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS acquired a new stake in Korro Bio in the 4th quarter valued at about $53,000. Quest Partners LLC grew its stake in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock valued at $59,000 after acquiring an additional 1,124 shares during the last quarter. AlphaQuest LLC grew its stake in Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after acquiring an additional 412 shares during the last quarter. Brown Brothers Harriman & Co. boosted its stake in shares of Korro Bio by 251.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock worth $95,000 after purchasing an additional 2,041 shares during the last quarter. Finally, Vestcor Inc purchased a new stake in shares of Korro Bio during the third quarter worth about $100,000. 13.18% of the stock is owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).